[go: up one dir, main page]

PE20171790A1 - ANTI-CEACAM6 ANTIBODIES AND THEIR USES - Google Patents

ANTI-CEACAM6 ANTIBODIES AND THEIR USES

Info

Publication number
PE20171790A1
PE20171790A1 PE2017001579A PE2017001579A PE20171790A1 PE 20171790 A1 PE20171790 A1 PE 20171790A1 PE 2017001579 A PE2017001579 A PE 2017001579A PE 2017001579 A PE2017001579 A PE 2017001579A PE 20171790 A1 PE20171790 A1 PE 20171790A1
Authority
PE
Peru
Prior art keywords
human
antigen
ceacam6
nca
antibodies
Prior art date
Application number
PE2017001579A
Other languages
Spanish (es)
Inventor
Jorg Willuda
Mark Trautwein
Uwe Gritzan
Christoph Freiberg
Frank Dittmer
Dorian Schonfeld
Julian Marius Gluck
Jessica Pinkert
Eva-Maria Gutierrez
Sven Golfier
Simon Holton
Philip Beckhove
Yingzi Ge
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PE20171790A1 publication Critical patent/PE20171790A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Regiones de union al antigeno y anticuerpos recombinantes y fragmentos funcionales que contienen aquellas regiones de union al antigeno que sean especificas de la CEACAM6 (molecula de adhesion celular relacionada con el antigeno carcinoembrionario 6, CD66c, antigeno no especifico de reaccion cruzada, NCA, NCA- 50/90) humana y de Macaca fascicularis, y que no presentan una reaccion cruzada significativa con la CEACAM1 humana, la CEACAM3 humana y la CEACAM5 humana mas estrechamente relacionadas. La invencion provee ademas metodos para generar este tipo de anticuerpos. Por lo tanto, los anticuerpos se pueden usar para tratar el cancer y otros trastornos y condiciones asociadas con la expresion de la CEACAM6. La invencion tambien provee secuencias de acidos nucleicos que codifican los anticuerpos precedentes, vectores que contienen los mismos, composiciones farmaceuticas y conjuntos de elementos con instrucciones para su usoRecombinant antibody and antigen-binding regions and functional fragments that contain those antigen-binding regions that are specific to CEACAM6 (cell adhesion molecule related to carcinoembryonic antigen 6, CD66c, non-specific cross-reactive antigen, NCA, NCA- 50/90) human and Macaca fascicularis, and which do not show a significant cross-reaction with the more closely related human CEACAM1, human CEACAM3 and human CEACAM5. The invention further provides methods for generating this type of antibody. Therefore, the antibodies can be used to treat cancer and other disorders and conditions associated with the expression of CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and sets of elements with instructions for their use.

PE2017001579A 2015-03-23 2016-03-21 ANTI-CEACAM6 ANTIBODIES AND THEIR USES PE20171790A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15160292 2015-03-23

Publications (1)

Publication Number Publication Date
PE20171790A1 true PE20171790A1 (en) 2017-12-28

Family

ID=52692556

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001579A PE20171790A1 (en) 2015-03-23 2016-03-21 ANTI-CEACAM6 ANTIBODIES AND THEIR USES

Country Status (28)

Country Link
US (3) US10584167B2 (en)
EP (2) EP3628688A1 (en)
JP (2) JP6815329B2 (en)
KR (1) KR102749339B1 (en)
CN (1) CN107743495B (en)
AR (1) AR104047A1 (en)
AU (1) AU2016236270B2 (en)
BR (1) BR112017020373A2 (en)
CA (1) CA2980390A1 (en)
CY (1) CY1122627T1 (en)
DK (1) DK3274370T3 (en)
ES (1) ES2768784T3 (en)
HK (1) HK1246312A1 (en)
HR (1) HRP20192280T1 (en)
HU (1) HUE048111T2 (en)
IL (1) IL254534B (en)
LT (1) LT3274370T (en)
MX (1) MX376973B (en)
PE (1) PE20171790A1 (en)
PL (1) PL3274370T3 (en)
PT (1) PT3274370T (en)
RS (1) RS59878B1 (en)
RU (1) RU2739163C2 (en)
SG (1) SG11201707800QA (en)
SI (1) SI3274370T1 (en)
TW (1) TWI719969B (en)
WO (1) WO2016150899A2 (en)
ZA (1) ZA201707138B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3274370T1 (en) 2015-03-23 2020-02-28 Bayer Pharma Aktiengesellschaft Antibodies against CEACAM6 and their use
JP7011764B2 (en) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody adjuvant complex
WO2018070936A1 (en) * 2016-10-10 2018-04-19 Singhealth Services Pte Ltd Anti-ceacam6 antibodies and methods of use
MX2019005491A (en) 2016-11-14 2019-08-12 Dinona Antibody binding specifically to cd66c and use thereof.
KR102014400B1 (en) * 2017-01-05 2019-08-28 한국생명공학연구원 Anti-ceacam6 chimeric antigen receptor specifically binding to ceacam6
CN111148760A (en) * 2017-02-27 2020-05-12 卡拉斯医疗有限公司 Antibody constructs and methods of treating cancer
US11529371B2 (en) 2017-04-24 2022-12-20 Memorial Sloan Kettering Cancer Center Anti-CD33 antibody agents
CN111065653A (en) * 2017-05-23 2020-04-24 中央研究院 Conditional endocytosis of pegylated reagents by pre-targeted bispecific polyethylene glycol-binding antibodies for diagnostic and therapeutic uses
CN117820498A (en) * 2017-08-10 2024-04-05 盖立复诊断解决方案公司 Compositions, methods and/or kits comprising recombinant human CD38 extracellular domain
KR102134954B1 (en) 2018-01-08 2020-07-16 충북대학교 산학협력단 siRNA for inhibiting CEACAM6 expression and therapeutic agent for adenocarcinoma comprising thereof
CA3091181A1 (en) * 2018-02-13 2019-08-22 Precision Biologics, Inc. Methods and compositions for targeting treg cells
JP7563979B2 (en) * 2018-03-13 2024-10-08 タスク セラピューティクス リミテッド Anti-CD25 for tumor-specific cell depletion
KR102373502B1 (en) * 2018-05-14 2022-03-11 주식회사 금호에이치티 Use of prevention and treatment of disease related to myeloid-derived suppressor cell and use thereof
WO2019223733A1 (en) * 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use
MX2020013122A (en) * 2018-06-03 2021-04-13 Lamkap Bio Beta Ltd Bispecific antibodies against ceacam5 and cd47.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20220010017A1 (en) * 2018-11-14 2022-01-13 Bayer Aktiengesellschaft Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
AU2019407364A1 (en) * 2018-12-19 2021-05-27 Bayer Aktiengesellschaft Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020244528A1 (en) * 2019-06-04 2020-12-10 上海吉倍生物技术有限公司 Anti-ceacam5 monoclonal antibody, preparation method therefor and use thereof
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
WO2021178951A1 (en) * 2020-03-06 2021-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor targeted fluorescence guidance for intraoperative margin assessment
CN111533808B (en) * 2020-03-10 2021-02-09 南京医科大学 Chimeric antigen receptor modified T cell capable of autocrine TLR4 scFv and targeting cMet and application thereof
CN113637073B (en) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 BCMA antibody, preparation and application thereof
CN116621980A (en) * 2020-10-21 2023-08-22 北京纽安博生物技术有限公司 anti-CEACAM 6 single domain antibody, fusion protein and application thereof
WO2022116079A1 (en) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 Humanized anti-ceacam5 antibody, and preparation method therefor and use thereof
EP4259123A4 (en) * 2020-12-11 2024-11-20 Materia Therapeutics Inc. CANCER TREATMENT WITH BOSENTAN IN COMBINATION WITH A CHECKPOINT INHIBITOR
WO2022133089A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea6 binding molecules and uses thereof
CN112521509B (en) * 2020-12-23 2022-07-08 姚雪英 anti-CEACAM 5 humanized antibody, conjugate thereof and application thereof
IL310773A (en) 2021-09-02 2024-04-01 Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
EP4496595A1 (en) 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
CN116196415B (en) * 2022-12-07 2023-08-01 浙江省肿瘤医院 Mixed preparation for sensitizing PD-1 antibody and method of use thereof
WO2024243217A1 (en) * 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JP4436457B2 (en) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー Protein / (poly) peptide library
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE296315T1 (en) 1997-06-24 2005-06-15 Genentech Inc COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
JP4460155B2 (en) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート Humanization of mouse antibodies
ES2532910T3 (en) 1998-04-02 2015-04-01 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (en) 2002-12-16 2010-07-22 Genentech Inc IMMUNOGLOBULIN VARIANTS AND ITS USES
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
CN103059138B (en) 2005-05-09 2015-10-28 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and use anti-PD-1 antibody to carry out the method for Therapeutic cancer
ME02260B (en) 2005-07-01 2016-02-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST A PROGRAMMED TYPE 1 DEATH LIGAND (PD-L1)
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
HRP20131167T1 (en) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. HUMAN RECEPTOR PROGRAMMED DEATHS ANTIBODIES PD-1
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US8404812B2 (en) 2010-02-26 2013-03-26 Dinona Inc. Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
ES2664989T3 (en) * 2010-10-01 2018-04-24 National Research Council Of Canada ANTI-CEACAM6 antibodies and their uses
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
RS61033B1 (en) 2011-11-28 2020-12-31 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
RU2493166C1 (en) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Nanoantibody specifically binding cea protein, method of its usage for detection of this protein
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10131712B2 (en) 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
DK3044234T3 (en) 2013-09-13 2020-05-18 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
SI3274370T1 (en) * 2015-03-23 2020-02-28 Bayer Pharma Aktiengesellschaft Antibodies against CEACAM6 and their use
SI3277321T1 (en) 2015-04-01 2024-11-29 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
PL3443009T3 (en) 2016-04-12 2022-01-31 Symphogen A/S Anti-tim-3 antibodies and compositions
KR102366813B1 (en) 2016-05-27 2022-02-24 아게누스 인코포레이티드 Anti-TIM-3 Antibodies and Methods of Using Same
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JOP20190013A1 (en) 2016-08-25 2019-01-31 Lilly Co Eli Anti-tim-3 antibodies
MX2019005491A (en) 2016-11-14 2019-08-12 Dinona Antibody binding specifically to cd66c and use thereof.
CA3049536A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies

Also Published As

Publication number Publication date
US20180162940A1 (en) 2018-06-14
BR112017020373A2 (en) 2018-06-05
EP3628688A1 (en) 2020-04-01
WO2016150899A3 (en) 2016-11-17
PL3274370T3 (en) 2020-05-18
EP3274370B1 (en) 2019-11-20
MX2017012278A (en) 2018-05-23
AR104047A1 (en) 2017-06-21
SI3274370T1 (en) 2020-02-28
JP6815329B2 (en) 2021-01-20
US11773164B2 (en) 2023-10-03
US10584167B2 (en) 2020-03-10
CY1122627T1 (en) 2021-03-12
US11866495B2 (en) 2024-01-09
AU2016236270A1 (en) 2017-10-12
IL254534A0 (en) 2017-11-30
PT3274370T (en) 2020-01-30
DK3274370T3 (en) 2020-02-17
KR20170128567A (en) 2017-11-22
RU2017137010A (en) 2019-04-23
CN107743495B (en) 2021-05-14
WO2016150899A2 (en) 2016-09-29
EP3274370A2 (en) 2018-01-31
US20200157214A1 (en) 2020-05-21
CA2980390A1 (en) 2016-09-29
IL254534B (en) 2021-12-01
TWI719969B (en) 2021-03-01
RU2739163C2 (en) 2020-12-21
HK1246312A1 (en) 2018-09-07
ZA201707138B (en) 2022-11-30
MX376973B (en) 2025-03-07
JP2021058199A (en) 2021-04-15
LT3274370T (en) 2020-02-10
US20200181261A1 (en) 2020-06-11
CN107743495A (en) 2018-02-27
JP2018510636A (en) 2018-04-19
SG11201707800QA (en) 2017-10-30
HRP20192280T1 (en) 2020-03-06
RU2017137010A3 (en) 2019-12-12
HUE048111T2 (en) 2020-05-28
KR102749339B1 (en) 2025-01-03
TW201713693A (en) 2017-04-16
AU2016236270B2 (en) 2022-01-27
ES2768784T3 (en) 2020-06-23
JP7185379B2 (en) 2022-12-07
RS59878B1 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
PE20171790A1 (en) ANTI-CEACAM6 ANTIBODIES AND THEIR USES
CL2018002490A1 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies that specifically bind to cd3 and / or cd123. (divisional application 201701866)
CO2020000357A2 (en) Novel T-cell receptors, and immunotherapy using the same
CL2019000119A1 (en) Bispecific antibody binding proteins that specifically bind cd3 and cd123.
CL2019002717A1 (en) Enhanced antigen-binding receptors.
AR110676A1 (en) TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
PE20191493A1 (en) T-LYMPHOCYTE RECEPTORS AND IMMUNE THERAPIES BASED ON THE USE OF THE SAME AGAINST PRAME-POSITIVE CANCERS
MX2020004741A (en) Novel engineered t cell receptors and immune therapy using the same.
DOP2018000212A (en) MOLECULES OF UNION TO BCMA AND METHODS OF USE OF THE SAME
MX395287B (en) NEW T LYMPHOCYTE RECEPTORS AND IMMUNOTHERAPY BASED ON THEIR USE.
PE20190418A1 (en) ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES
EA201992755A1 (en) NEW MONOCLONAL ANTIBODIES FOR PROTEIN 4 ASSOCIATED WITH CYTOTOXIC T-Lymphocytes, (CTLA-4)
CL2016002689A1 (en) Humanized antibodies against the cell adhesion molecule related to carcinoembryonic antigen 1 (ceacam1)
ECSP22015276A (en) PROTEINS COMPRISING KALLYCREIN-RELATED PEPTIDASE 2 ANTIGEN-BINDING DOMAINS AND THEIR USES
AR110114A1 (en) ANTIBODIES AGAINST b-AMYLOID PIROGLUTAMATO AND ITS USES
CY1119051T1 (en) ANTI-C4.4A ANTIBODIES AND THEIR USES
EA202091982A1 (en) Chimeric antigenic receptor to the receptor of IL-13 ALPHA 2 (IL13R2) for tumor-specific T-cell immunotherapy
PE20201149A1 (en) HLA-A2 / WT1 BINDING ANTIBODIES
PE20240761A1 (en) PSMA BINDING PROTEINS AND USES OF THESE
ECSP23050855A (en) COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND THEIR METHODS OF USE
PE20090981A1 (en) IMPROVED NOGO-A BINDING MOLECULES AND PHARMACEUTICAL USE OF THEM
AR126595A1 (en) IMMUNE CELLS THAT EXPRESS CAR THAT SPECIFICALLY TARGET MESOTELIN AND USES THEREOF
EA201991151A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA201992002A1 (en) T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION
EA201992583A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION